KV PHARMA LICENSES WOMEN'S HEALTHCARE PRODUCTS FOR MEXICO

US-based KV Pharmaceutical has announced agreements to market two of its women's healthcare products in Mexico. Under the deal, Mexican manufacturer and distributor RIMSA is to distribute the US company's two single-dose vaginal creams, Gynazole-1 and the recently US FDA-approved Clindesse, with the former product launching by March 2006. RIMSA has a sales force of some 200, while the local market for vaginal anti-infectives is estimated to be worth some US$25mn annually. KV is due to receive an undisclosed amount of license and manufacturing revenue under the terms of the contract.

KV claims that Gynazole-1 has captured a market share of some 30% of the US branded prescription cream segment. The product is indicated for vulvovaginal candidiasis. Clindesse, meanwhile, is a therapy for non-pregnant patients with bacterial vaginosis, a leading cause of vaginitis.